Status:

COMPLETED

Alaska Native Family-Based, Financial Incentives Intervention for Smoking Cessation

Lead Sponsor:

Mayo Clinic

Collaborating Sponsors:

National Institute on Drug Abuse (NIDA)

Alaska Native Tribal Health Consortium

Conditions:

Smoking Cessation

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The objective of the proposed study is to develop and beta-test a culturally adapted, Alaska Native family-based incentives intervention for smoking cessation.

Detailed Description

Aim 1 has two phases: In Aim 1/Phase 1, we will use qualitative in-depth individual interviews to culturally tailor and adapt the intervention. These interviews (n=36) will include Alaska Native or A...

Eligibility Criteria

Inclusion

  • Index Participants will be eligible if they:
  • Are an ANAI person (based on self-reported race/ethnicity) and reside in Alaska.
  • Are aged ≥ 18 years (legal smoking age in Alaska).
  • Self-report smoking in the past 7 days, biochemically verified with saliva cotinine ≥ 30 n/ml (positive Alere iScreen result) for Phase 2.
  • Smoked ≥ 3 cigarettes per day (cpd) over the past 3 months.
  • If other tobacco or nicotine product used, cigarettes are the main tobacco product used.
  • Are considering or willing to make a quit attempt.
  • Own or have access to a mobile phone or tablet with Internet and text messaging capabilities, or will be loaned an iPad mini for the study duration.
  • Nominate one adult family member who will enroll.
  • Index Participants

Exclusion

  • Used pharmacotherapy or a stop smoking program within the past 3 months.
  • Another person in the household is enrolled as the index participant.
  • Smokes marijuana at least once a week and not willing to quit for study (interferes with breath test) in Phase 2
  • Family Member Participants, regardless of smoking status or residence with the index participant, will be eligible if they:
  • Are ≥ 18 years old.
  • Are defined as family by the index participant.
  • Own or have access to a mobile phone or tablet with internet and text messaging capabilities or will be loaned an iPad mini for the study duration.
  • Both men and women and those from non-ANAI racial/ethnic groups.
  • Family members may only support one index participant.
  • Alaska Tribal Health System stakeholders (Phase 1 only):
  • \- Input from healthcare providers, cessation specialists, and THO leaders will be gathered to understand potential facilitators and barriers to adoption of the intervention within the ATHS. The ANTHC team will invite individuals to participate through phone and email communications.

Key Trial Info

Start Date :

November 1 2022

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

April 28 2024

Estimated Enrollment :

58 Patients enrolled

Trial Details

Trial ID

NCT05413265

Start Date

November 1 2022

End Date

April 28 2024

Last Update

March 18 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Mayo Clinic

Rochester, Minnesota, United States, 55905